IngredientsBulnesia sarmientoi, commonly known as palo santo or guaiacwood, is a slow-growing deciduous tree in the family Zygophyllaceae native to the dry forests of the Gran Chaco ecoregion spanning Argentina, Paraguay, Bolivia, and eastern Brazil. The binomial Bulnesia sarmientoi was established by Paul Günther Lorentz ex August Heinrich Rudolf Grisebach in 1879, based on specimens from the Gran Chaco region collected during Lorentz's expedition sponsored by the Argentine government. The specific epithet sarmientoi honors Domingo Faustino Sarmiento (1811–1888), Argentine educator, statesman, and president (1868–1874), who supported Lorentz's botanical surveys and promoted scientific exploration in the region.
The species occupies a position within the order Zygophyllales, family Zygophyllaceae, as recognized by the Angiosperm Phylogeny Group IV classification system updated in 2016, which places the family alongside Krameriaceae in this rosid order of eudicots. The species belongs to the genus Bulnesia, a small group of approximately eight to nine species primarily endemic to arid and semi-arid regions of South America, historically treated as comprising two subgenera: Gonopterodendron and Bulnesia.
The taxonomy of the species has been in flux. The tree has recently been reclassified as Gonopterodendron sarmientoi. Its wood is often traded as "Paraguay lignum vitae," since it has properties and uses similar to the "true" lignum vitae trees of genus Guaiacum, which are close relatives. Another trade name is "vera" or "verawood," which may also refer to the even more closely related B. arborea. Another common but rather ambiguous name is palo santo (Spanish: "holy stick"), which it shares with the unrelated species Bursera graveolens. This species confusion has significant practical consequences: the Bursera graveolens more commonly used in aromatherapy is a tree that originates in the dry forests of Ecuador and Perú, a highly revered tree praised for its pleasant aromatic qualities for generations, and is taxonomically entirely unrelated to Bulnesia sarmientoi.
The species is a slow-growing deciduous tree found in tropical regions of South America, particularly Argentina and Paraguay. Trees grow up to 18 meters tall and are sometimes referred to by the common Spanish name "Palo Santo," which translates to "Holy Stick." The heartwood is brown, black, and green (varying in color from light olive green to chocolate brown), with streaks. The sapwood is mostly thin and light yellow. The basic specific gravity of this wood is between 0.92 and 1.1 g/cm³, making it one of the densest woods in the world. The tree's slow growth rate — reaching maturity over decades — and low natural regeneration rates amplify its ecological vulnerability.
Bulnesia sarmientoi (BS, Palo Santo) is an endemic tree in the Gran Chaco area around Argentina, Bolivia, Brazil, and Paraguay borders, belonging to the Zygophyllaceae family. The wood waste of BS is often used to extract essential oils, which have a balmy rose or violet aroma and have been used in perfumery and aromatherapy.
The species yields several commercially relevant preparations:
The wood is greatly appreciated due to its resistance to insect attack and hardness. The essential oil, which is commercially obtained, is mainly used in perfumery and cosmetic industries. Guaiac wood oil is used extensively in perfume compositions for its excellent fixative properties.
During the Spanish colonial era (16th–19th centuries) in the Gran Chaco region spanning present-day Argentina, Paraguay, Bolivia, and Brazil, Bulnesia sarmientoi (palo santo) was primarily exploited on a small, localized scale by indigenous communities and early settlers for its exceptionally dense wood and aromatic resin. In the past, the harvest of the species by various indigenous peoples of the region and its use by other local populations did not pose a threat to its conservation.
Palo santo has been traditionally employed in South American folk medicine for its purported analgesic, anti-inflammatory, and wound-healing effects, with bark decoctions or powders applied topically or ingested for pain relief and skin ailments. The wood is appreciated for the skin-healing properties of its essence.
Natives of the Chaco region employ the bark to treat stomach problems. The essential oil and the bark are used topically as wound-healing agents, and as insect repellents. The leaves' decoction is indicated for the treatment of tuberculosis in traditional ethnobotanical records from the region.
Beyond wound healing and analgesic use, BS has been used as a traditional medicine in analgesic, wound healing, anti-inflammation, antioxidant, and bactericidal activities, to improve serum lipid profiles, and to treat gastrointestinal problems.
The Weenhayek people of the Gran Chaco province of Tarija, Bolivia, are documented as among the indigenous communities incorporating Bulnesia sarmientoi within their pharmacopoeia. An ethnobotanic inventory of the medicinal plants of the Weenhayek was compiled with the participation of traditional physicians of the region.
The wood waste of BS is often used to extract essential oils and has been used in perfumery and aromatherapy. The wood ignites easily despite being so dense and produces a fragrant smoke. Small pieces of the wood are also used as a form of natural incense in spiritual rituals.
Guaiacwood oil is acknowledged by the German Commission E Monographs and the British Herbal Pharmacopoeia for rheumatism and rheumatoid arthritis. It has also been used for gout and fluid retention. Some sources recommend guaiacwood as a venous and lymphatic decongestant, as well as for pelvic congestion that contributes to PMS.
The essential oil of Bulnesia sarmientoi is chemically complex. The volatile oil has been characterized by GC × GC-TOF-MS analysis. Major components are guaiol and bulnesol, followed by hanamyol. The enhanced sensitivity and superior resolution of GC × GC resulted in the identification of thus-far unreported oil constituents including β-guaiene, guaioxide, elemol, germacrene-B, eudesm-5-en-11-ol, γ-eudesmol, α-eudesmol, and (−)-hanamyol.
In a gas chromatography-mass spectrometry (GC-MS) study of supercritical fluid extract (BSE), the GC-MS analytical results showed that BSE contains at least 25 ingredients, of which 10 compounds were identified using the NIST spectral database. The main constituents of BSE were identified as α-guaiene (relative content RC = 34.0%), (−)-guaiol (RC = 28.7%), (−)-nortrachelogenin (RC = 8.3%), β-eudesmol (RC = 6.4%), and β-caryophyllene (RC = 1.4%).
The oil may be used as a starting material for the synthesis of guaiazulene (C₁₅H₁₈), which has anti-inflammatory properties, and for the production of guaiyl acetate.
The anti-inflammatory properties attributed to Bulnesia sarmientoi derive primarily from its sesquiterpene constituents. Guaiol, the dominant compound, has been studied for mTOR pathway inhibition: guaiol has been discovered to be a more powerful mTOR inhibitor than rapamycin, reducing non-small-cell lung cancer (NSCLC) cell viability by inhibiting mTOR signaling. Guaiol reduces the phosphorylation (Ser2481) of mTOR, reducing AKT activity (mTORC2 substrates), and further enhances the inhibitory activity of p70 S6K or 4E-BP1 (mTORC1 substrates), reducing the viability of NSCLC cells.
The aqueous extract of BS (aqBSE) has exhibited anti-platelet activity and inhibition of thrombus formation via MAP kinase inhibition. This finding was reported by Kamruzzaman, Endale, and colleagues in a 2010 study published in the Journal of Ethnopharmacology, documenting the inhibitory effects of Bulnesia sarmienti aqueous extract on agonist-induced platelet activation and thrombus formation involving mitogen-activated protein kinases (J. Ethnopharmacol. 2010;130:614–620).
Necrosis of A549 and H661 lung cancer cells was detected by flow cytometry with Annexin V-FITC/PI double staining. The cytotoxic effect of BSE on cancer cells was significantly reverted by Nec-1 pretreatment, and BSE induced TNF-α and RIP-1 expression in the absence of caspase-8 activity. This pattern of activity indicates that BSE induces programmed necrosis (necroptosis) rather than classical apoptosis.
Guaiol, bulnesol, and hanamyol have been identified as the major components of the essential oil with varying insecticidal effects. The essential oil demonstrated antifungal activity against Fusarium species, with specific efficacy of hanamyol.
In the food industry, guaiac resin is used as an antioxidant to preserve animal fats. Since guaiac resin is also a sensitive chemical reagent to oxidases and peroxidases, it is additionally used to detect blood in urine and faeces (the haemoccult test). This latter application — the guaiac fecal occult blood test (gFOBT) — is one of the most extensively validated clinical applications of guaiac chemistry globally, though it relies on the resin's peroxidase-like reactivity rather than any direct health benefit from the tree itself.
Evidence level: Preclinical only (in vitro and animal). No human clinical trials.
BS has long been used as an analgesic, wound-healing, and anti-inflammatory medicinal plant. The aqueous extract of its bark has been demonstrated to have anti-cancer activity. One study investigated the anti-proliferative and anti-metastatic effects of BS supercritical fluid extract (BSE) on the A549 and H661 lung cancer cell lines.
Cytotoxicity on cancer cells was assessed by MTT assay. After 72 hours of treatment of A549 and H661 cells, the IC₅₀ values were 18.1 and 24.7 μg/mL, respectively. The cytotoxicity on MRC-5 normal cells was relatively lower (IC₅₀ = 61.1 μg/mL). BSE arrested lung cancer cells at the S and G2/M growth phases.
By wound healing and Boyden chamber assays, the inhibitory effects of BSE on the migration and invasion of lung cancer cells were elucidated, indicating anti-metastatic potential in this in vitro model.
An earlier study, reported by Mollah and colleagues (2009), examined the growth-inhibitory effects of a Bulnesia sarmienti aqueous extract on A549 cells in vitro and S180 cells in vivo (Immunopharmacol. Immunotoxicol. 2009;31:492–498). This in vivo animal study on sarcoma 180 tumor-bearing mice, cited in subsequent reviews, demonstrated tumor size reduction, but this remains animal-level data with no human translation established.
Despite these promising findings, clinical evidence supporting the health benefits of Bulnesia sarmientoi in humans remains limited. Most available studies are preclinical, and robust human trials are needed to confirm efficacy and safety.
Evidence level: In vitro preclinical only. No human clinical trials.
In vitro antimycobacterial activity of the ethanolic extract obtained from the wood of Bulnesia sarmientoi and its chemical composition were studied. Preliminary phytochemical analysis showed the presence of steroids and/or triterpenes and tannins. GC/MS fingerprint analysis identified guaiol and bulnesol as main volatile components. The extract showed activity against Mycobacterium tuberculosis H37Rv strain with a minimal inhibitory concentration (MIC) of 50 μg/mL, using the microplate Alamar Blue assay. These results suggest that the extract could be a source of antimicrobial substances against M. tuberculosis.
It is important to note that an MIC of 50 μg/mL, while demonstrating in vitro activity, is considered moderate potency in the context of antimycobacterial drug discovery. No human studies or clinical trials have been conducted investigating B. sarmientoi preparations for the treatment of tuberculosis.
Evidence level: In vitro preclinical only.
The oil and its constituents were assayed for antifungal action against Fusarium spp. and phytotoxicity to Lactuca sativa. Among the pure compounds tested, bulnesol had a low-moderate effect on Fusarium moniliforme while hanamyol had a strong effect on Fusarium solani. Neither the oil nor its constituents were phytotoxic to Lactuca sativa, showing 100% germination rate.
Evidence level: In vitro and ex vivo preclinical. No human clinical trials.
A published study (Kamruzzaman et al., Journal of Ethnopharmacology, 2010) demonstrated that the aqueous extract of BS exhibited anti-platelet activity and inhibition of thrombus formation via MAP kinase inhibition. This study employed platelet activation assays and is the primary evidence base for the cardiovascular claims surrounding this plant. The study has not been replicated in human clinical trials.
Evidence level: Traditional use; limited preclinical data. No human clinical trials.
BS has long been used as an analgesic, wound-healing and anti-inflammatory medicinal plant. The scientific basis for these properties rests primarily on the known pharmacology of constituent sesquiterpene alcohols (particularly guaiol and β-caryophyllene). In vivo study in mice showed guaiol has anti-nociceptive and anti-inflammatory effects at tested doses. However, there are no controlled human trials specifically testing Bulnesia sarmientoi preparations for pain or inflammation outcomes.
Evidence level: Traditional / ethnobotanical only. No formal clinical trials identified.
The essential oil and the bark are used topically as wound-healing agents by local populations throughout the Chaco region. Palo santo is appreciated for the skin-healing properties of its essence. No controlled human studies on wound healing outcomes have been published.
Evidence level: In vitro and laboratory bioassay. Relevant to agricultural / veterinary application, not human supplementation.
Both B. sarmientoi oil and isolated compounds caused almost 100% mortality in larvae of Rhipicephalus microplus from a susceptible strain at concentrations above 0.1%. At 0.01%, guaiol induced 50% larval mortality. The insecticidal effect on Spodoptera littoralis, Rhopalosiphum padi, and Myzus persicae was studied. Guaiol affected the aphids in a dose-response fashion, showing low efficiency, while bulnesol and hanamyol were inactive.
Based on available traditional ethnobotanical records and published preclinical research, Bulnesia sarmientoi and its extracts have been associated with the following body systems:
No standardized clinical dosages exist for Bulnesia sarmientoi in any preparation. The following concentrations or doses are reported only as they appear in specific research publications:
No human pharmacokinetic data, minimum effective doses, or therapeutic dosing ranges for any indication have been established in published clinical research.
Clinical evidence supporting the health benefits of Bulnesia sarmientoi in humans remains limited. Most available studies are preclinical, and robust human trials are needed to confirm its efficacy and safety. No comprehensive human safety or toxicology studies for oral supplementation of B. sarmientoi extract have been published in peer-reviewed literature.
Essential oil from B. sarmientoi is associated with low toxicity to mammals, based on the available bioassay data context. However, this characterization stems from veterinary and agricultural toxicology data rather than human safety trials.
The documented antiplatelet and antithrombotic mechanism of the aqueous extract — anti-platelet activity and thrombus formation inhibition via MAP kinase inhibition — raises a theoretically significant interaction concern with anticoagulant and antiplatelet pharmaceutical drugs (e.g., aspirin, clopidogrel, warfarin). This has not been clinically characterized but represents a biologically plausible pharmacodynamic interaction warranting attention.
In the supercritical fluid extract study, after 72 h treatment of cancer cell lines, the IC₅₀ values were 18.1 and 24.7 μg/mL for A549 and H661 cells, respectively, while cytotoxicity on MRC-5 normal cells was relatively lower (IC₅₀ = 61.1 μg/mL). While this differential suggests some degree of selectivity for malignant cells in vitro, the implications for human safety at any achievable in vivo concentration remain entirely unknown.
A critical safety consideration for consumers of Bulnesia sarmientoi products is the risk of species adulteration and illegal supply chains. The species was listed as endangered in the 2018 publication of the IUCN Red List, due to the deforestation of Gran Chaco and strong global demand for its wood, extracts, and essential oils since 2001. IUCN estimates indicate that over three generations the global population will decline by around 50%.
The species has been included in Appendix II of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) since 5 March 2010, following adoption at the 15th Conference of the Parties, to regulate trade in logs, sawn wood, veneer sheets, plywood, and essential oils derived from the species. This listing requires export permits and certificates of origin to ensure trade does not threaten survival.
The species faces unsustainable exploitation due to increased international demand, particularly from China since 2002. China accounted for 95% of trade volume from exporting countries during the period that prompted CITES review.
The shared common name "palo santo" between Bulnesia sarmientoi and the entirely unrelated Bursera graveolens creates documented mislabeling risks in commercial products. Bulnesia sarmientoi is an entirely different species of tree that is listed on the CITES Appendix and the IUCN Red List database as an endangered species. The common name of this species is also "Palo Santo." This species is endangered due to its use as a lumber material for commercial-scale construction. Consumers purchasing products labeled "palo santo" may receive material from either species, with different phytochemical profiles and different regulatory statuses.
The essential oil is widely used in perfumery and cosmetics without established formal contraindications in the peer-reviewed scientific literature. Its high viscosity means it requires dilution before topical application. No formal clinical data on sensitization rates, phototoxicity, or reproductive toxicity for Bulnesia sarmientoi wood oil specifically have been found in peer-reviewed sources.
The guaiac resin derived from related Guaiacum species, and potentially from Bulnesia sarmientoi as well, has a well-established role in fecal occult blood testing. Since guaiac resin is a sensitive chemical reagent to oxidases and peroxidases, it is used to detect blood in urine and faeces (haemoccult test). This detection is based on the oxidation of α-guaiaconic acid to the quinoid guaiac blue (furoguaiacin blue). Consumption of guaiac-containing products in significant amounts could theoretically interfere with fecal occult blood test results, though this has not been specifically documented for B. sarmientoi extracts in human studies.
In the United States, Bulnesia sarmientoi wood oil appears in the National Institutes of Health's NCATS database as an ingredient found in cosmetic products, with an entry noting possible marketing outside the United States. The ingredient is also listed in the FDA's DailyMed database in the context of topical cosmetic formulations. No FDA-approved therapeutic claims exist for any preparation of this plant.
All international trade in logs, sawn wood, veneer sheets, plywood, and essential oils derived from the species requires CITES export permits and certificates of origin. This has direct implications for the legal commercial supply of guaiacwood oil globally.
The overall weight of scientific evidence for Bulnesia sarmientoi can be summarized as follows: Preliminary in vitro and animal studies suggest that the compounds in B. sarmientoi may contribute to antioxidant activity and support immune function. Some research indicates that certain components of the oil can modulate oxidative stress pathways implicated in chronic diseases. Despite these promising findings, clinical evidence supporting the health benefits in humans remains limited. No randomized controlled human trials have been published on any extract or preparation of this species for any therapeutic indication. All mechanistic and efficacy data derive from cell-culture and animal studies, and should not be extrapolated to human clinical outcomes without confirmatory human research.
Health conditions that Bulnesia sarmientoi may help support.
Body systems that Bulnesia sarmientoi may help support.
Go back